Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Publication of U.S. CPT® Codes and Related Reimbursement Rates for XIAFLEX®
Date:11/2/2011

/p>

$102.95INJECTION, ENZYME (EG, COLLAGENASE), PALMAR FASCIAL CORD (IE, DUPUYTREN'S CONTRACTURE)  20527

$75.77Finger Extension- MANIPULATION, PALMAR FASCIAL CORD (IE, DUPUYTREN'S CORD), POST ENZYME INJECTION (EG, COLLAGENASE), SINGLE CORD  (10 day global)

26341

$98.53 Application of finger splint; static

29130

$39.07In addition to the above procedure codes, physicians treating a Medicare patient typically use XIAFLEX J code 0775 to bill for the cost of the drug at the average selling price (ASP) plus 6 percent.

The above rates are calculated using the final 2012 relative value unit (RVU) for each of the above codes and multiplying it by the 2011 conversion factor (i.e. RVU x conversion factor = reimbursement rate).  Without a change in the law from Congress, Medicare payment rates to providers that are paid under the Medicare Physician Fee Schedule will be reduced by 27.4 percent (via the proposed 2012 conversion factor) for services in 2012.  This is the eleventh time the Sustainable Growth Rate (SGR) formula has proposed a payment cut although the reductions have been averted through legislation in ten of the past eleven years, with the exception of allowing the reduction to stand in 2002.  

About Dupuytren's contracture Dupuytren's contracture is a chronic condition that affects the connective tissue that lies beneath the skin in the palm. The disease is progressive in nature. Typically, skin pits then nodules develop in the palm as collagen deposits accumulate. As the disease progresses, the collagen deposits form a cord that stretches from the palm of the hand to the base of the finger. Once this cord develops, the patient's fingers contract and the function of the hand is impaired. The incidence of Dupuytren's disease, inclusive of pits, nodules and cords, is highest in Caucasians, historically those of Northern European descent, with a global prevalence of three to six percen
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Auxilium Pharmaceuticals to Announce Third Quarter 2011 Results and Conduct Conference Call on Monday, October 31, 2011
2. Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytrens Contracture in E-poster at ASSH Meeting
3. Auxilium Pharmaceuticals Announces Positive Data from Commercial Patient Chart Review in E-posters at ASSH Meeting
4. Auxilium Pharmaceuticals, Inc. Announces Positive Top-Line Results from XIAFLEX® Multi-Cord Study
5. Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX®
6. Auxilium Pharmaceuticals Announces Investor Event to Occur at 2011 ASSH Meeting on September 9, 2011
7. Auxilium Pharmaceuticals to Present at the Stifel Nicolaus 2011 Healthcare Conference
8. Auxilium Pharmaceuticals, Inc. Announces Promotion of Dr. James P. Tursi to Chief Medical Officer
9. Auxilium Pharmaceuticals to Announce Second Quarter 2011 Results and Conduct Conference Call on Monday, August 1, 2011
10. Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytrens Contracture
11. Auxilium Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015  Delays in ... projects can slow down the decision-making process, resulting ... therefore, absolutely critical for biopharmaceutical companies to develop ... approval process for quicker and more meaningful insights. ... Best Practices, LLC, nearly three-quarters of benchmarked study ...
(Date:8/28/2015)... 2015 Research and ... of the "12th Annual Report and Survey ... to their offering. The 2015 12th ... and Production is the most recent study of ... projected future capacity and production. The report contains ...
(Date:8/28/2015)... 28, 2015 Research ... of the "Investigation Report on China,s Insulin ... Developed by Novo Nordisk, insulin aspart ... important drug for the treatment of diabetes. Compared ... acting insulin analog, starts working fast and reports ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2
... issued today a shareholders, letter discussing the results of its fiscal ... Dear Imagenetix shareholder - Following ... we commence the new fiscal year, I would like to address ...   Over the past few years our primary strategy ...
... July 12, 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ... 1 clinical trial of APD811, an orally bioavailable agonist ... treatment of pulmonary arterial hypertension, or PAH. ... tolerability and pharmacokinetics of 0.03 mg, 0.05 mg, 0.1 ...
Cached Medicine Technology:Imagenetix, Inc. Discusses March 31, 2011 Fiscal Year End Results and Future Focus 2Imagenetix, Inc. Discusses March 31, 2011 Fiscal Year End Results and Future Focus 3Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension 4
(Date:8/29/2015)... , ... August 29, 2015 , ... ... develops, may extend and improve the lives of patients, according to a newly ... Click here to read the full article. , The authors of the ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... Brands like ... with zero standard shipping costs. , “Before, a threshold of $49.00 was required ... select brands and items qualify for free standard shipping for customers regardless of the ...
(Date:8/29/2015)... ... August 29, 2015 , ... ProDrop Particles includes over 40 particle backdrops ... seconds of unique footage that users can shrink and stretch in the Final Cut ... Users can customize color, brightness, scale, speed, range, and flare attributes with intuitive controls ...
(Date:8/29/2015)... ... 29, 2015 , ... Hamstring strain have not ... tissue manipulation. Platelet rich plasma injections also have mixed results. Building core ... treatment outcomes. This localized treatment seems to address the symptoms and does offer ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health Sciences ... sell Arterosil and Arterosil HP, and that all claims and counterclaims have been ... Sciences, LLC (VHS) in the United States District Court for the Southern District ...
Breaking Medicine News(10 mins):Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... July 2008 Elsevier, a leading publisher of scientific, technical ... the official journal of the European Association of Urology ... , European Urology (also the "Platinum ... response and an international profile. To keep up with the ...
... Milwaukee-based Assurant Health, a,leading national provider of ... products, announces that Jennifer Kopps-Wagner has been,named ... immediately., Kopps-Wagner joined Assurant Health in ... company,s legal department. In her most recent ...
... LOUIS, July 16 Stereotaxis, Inc. (Nasdaq:,STXS) announced ... Heart and,Diabetes Center of North Reinland-Westphalia in Bad ... in a 10-year old boy. The team performed ... Pulmonary atresia is a congenital malformation of the ...
... New Center for Excellence Issue Brief, WASHINGTON, ... Government Excellence has issued its first issue brief ... Local Government Retiree Health,Benefit Plans: Myths and Realities. ... professor of economics and management, innovation, and,entrepreneurship in ...
... exemplify perseverance, ST. LOUIS, July 16 There,s ... their votes. They can vote online,and vote now for ... to elect,a new member of the 2008 Energizer(R) Keep ... of Fame celebrates everyday people whose,attributes and actions best ...
... 26 Grand Opening Festivities Will Include Health Education Fair,Tour ... "9 Steps to Optimum,Health", HUNTERSVILLE, N.C., July 16 ... is dedicated to successfully treating,diseases that were previously thought ... level of health, today announced that it will open,the ...
Cached Medicine News:Health News:Assurant Health Names Jennifer Kopps-Wagner Senior Vice President and General Counsel 2Health News:Stereotaxis Magnetic Navigation System Used to Successfully Treat an Inoperable Congenital Heart Defect in a 10-Year Old Patient 2Health News:Stereotaxis Magnetic Navigation System Used to Successfully Treat an Inoperable Congenital Heart Defect in a 10-Year Old Patient 3Health News:The Crisis in State and Local Government Retiree Health Benefit Plans: Myths and Realities 2Health News:Vote now for an Everyday Person with Never-Quit Spirit to join the Energizer(R) Keep Going(R) Hall of Fame 2Health News:Vote now for an Everyday Person with Never-Quit Spirit to join the Energizer(R) Keep Going(R) Hall of Fame 3Health News:Vote now for an Everyday Person with Never-Quit Spirit to join the Energizer(R) Keep Going(R) Hall of Fame 4Health News:Vote now for an Everyday Person with Never-Quit Spirit to join the Energizer(R) Keep Going(R) Hall of Fame 5Health News:North Carolina's Center For Advanced Medicine & Clinical Research Celebrates Opening of New LKN Medical Spa and Rejuvenation Center 2Health News:North Carolina's Center For Advanced Medicine & Clinical Research Celebrates Opening of New LKN Medical Spa and Rejuvenation Center 3
... Quality Analysis System) developed by Pablo Artal, ... first diagnostic tool for ophthalmology that provides ... system. Never before has an ophthalmologist had ... quality of vision. , ,OQAS works by ...
... -Chagas is an in-vitro diagnostic test ... to Trypanosoma cruzi in human serum/plasma. ... particle-agglutination assay using gelatin particles coated ... coated gelatin particles are agglutinated in ...
Inquire...
Elisa test for qualitative detection of Total antibodies to Trypanosoma Cruzi in human serum or plasma....
Medicine Products: